All Data
Lead Product(s): Cinacalcet
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Cinacalcet Tablets is a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2020
Details:
Testosterone gel, 1.62% (20.25 mg/1.25 gm actuation) is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and Hypogonadotropic hypogonadism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Endocrinology Product Name: Fensolvi
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
The study evaluated 45-mg subcutaneous leuprolide acetate administered at a 6-month interval in 64 GnRHa-naïve children with CPP. Fensolvi effectively suppressed reproductive hormones and stopped or caused regression of pubertal progression.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Semaglutide
Therapeutic Area: Endocrinology Product Name: Rybelsus
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,800.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 06, 2020
Details:
Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Emisphere for USD 1.350 billion. As part of the transaction, Novo Nordisk will also acquire related Eligen® SNAC royalty stream obligations owed to MHR Fund Management LLC (MHR).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dapagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Diurnal Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
EffRx anticipates a potential market launch for Alkindi in Switzerland by 2022 and will receive the exclusive rights to market and sell the product in Switzerland once the product has been registered.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: EffRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2020
Details:
Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Lyumjev
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 07, 2020
Details:
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Viagra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Farmalider SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
